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Background: Investigating how the immune system functions during malignancies is crucial to developing novel
therapeutic strategies. Natural killer (NK) cells, an important component of the innate immune system, play a vital
role in immune defense against tumors and virus-infected cells. The poor survival rate in colon cancer makes it
particularly important to develop novel therapeutic strategies. Oncolytic viruses, in addition to lysing tumor cells,
may have the potential to augment antitumor immune responses. In the present study, we investigate the role of
NK cells and how parvovirus H-1PV can modulate NK-cell mediated immune responses against colon carcinoma.
Methods: Human NK cells were isolated from the blood of healthy donors. The cytotoxicity and antibody-mediated
inhibition of NK cells were measured in chromium release assays. Phenotypic assessment of colon cancer and
dendritic cells was done by FACS. The statistical significance of the results was calculated with Student’s t test
(*p <0.05; **, p < 0.01; ***, p < 0.001).
Results: We show that IL-2-activated human NK cells can effectively kill colon carcinoma cells. Killing of colon
carcinoma cells by NK cells was further enhanced upon infection of the former cells with parvovirus H-1PV. H-1PV has
potent oncolytic activity against various tumors, yet its direct killing effect on colon carcinoma cells is limited. The
cytotoxicity of NK cells towards colon carcinoma cells, both mock- and H-1PV-infected, was found to be mostly
mediated by a combination of natural cytotoxicity receptors (NCRs), namely NKp30, 44, and 46. Colon carcinoma cells
displayed low to moderate expression of NK cell ligands, and this expression was modulated upon H-1PV infection.
Lysates of H-1PV-infected colon carcinoma cells were found to increase MHC class II expression on dendritic cells.
Conclusions: Altogether, these data suggest that IL-2-activated NK cells actively kill colon carcinoma cells and that this
killing is mediated by several natural cytotoxicity receptors (NCRs) in combination. Additionally, in association with
parvovirus H-1PV, IL-2-activated NK cells have the potential to boost immune responses against colon cancer.
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Natural killer cells constitute a separate lineage of lym-
phocytes capable of mediating early innate immune re-
sponses to viral infections and transformed malignant
cells. NK cells can recognize target cells, including tumor
cells, having downregulated MHC class I expression. They
can also recognize molecules that are not expressed in
normal cells but upregulated in transformed cells [1]. NK
cells express an array of receptors which modulate their
cytotoxicity towards tumor cells and infected cells. These
include NK-specific receptors called natural cytotoxicity
receptors (NCRs), represented by NKp30, NKp44, and
NKp46. NCRs act in concert with other receptors, such
as NKG2D and DNAM-1, to mediate NK-cell killing of
tumor cells when the corresponding ligands, variably
expressed by different tumors, are present. These ligands
are upregulated upon transformation and during viral in-
fection [2,3]. The NK receptors involved in killing colon
cancer cells have not yet been studied.
Colorectal cancer is the third most common cancer.
With an incidence of nearly 1 million cases yearly world-
wide, it is the fourth most frequent cause of cancer death
[4]. Although advances in colorectal cancer therapy have
improved treatment and survival, the 5-year survival rate
remains around 50%, making it necessary to develop novel
or complementary therapeutic strategies. Colorectal cancer
causes multifactorial changes in the host defense system,
including loss of HLA class I molecules, impaired NK cell
function, and immune escape, resulting in poor prognosis
[5]. It is the ambition of immunotherapy to counteract the
various escape effects, particularly in early tumors, and to
boost immune activity against tumors. To be successful,
immunotherapy must overcome immune escape mecha-
nisms and reduce tumor-induced immune suppression.
To subdue these impairments, cytokines, particularly IL-2,
appear as promising tools for relieving immune suppres-
sion and re-activating NK cells.
Novel therapeutic approaches such as virotherapy with
oncolytic viruses are also currently pursued as combination
strategies. Because oncolytic viruses specifically target and
kill tumor cells while sparing normal cells, they represent a
promising strategy for combating tumors. Parvoviruses
possess both oncolytic and oncosuppressive activities. They
are small (25-30 nm), non-enveloped particles housing a
5.1-kb single-stranded DNA genome expressing two major
non-structural proteins (NS1 and NS2) and two viral cap-
sid proteins (VP1 and VP2). Epidemiological studies in
humans have revealed a correlation between serological
evidence of parvoviral infection and a lower incidence of
certain cancers [6,7]. Parvoviruses are non-pathogenic in
humans, but human tumor cell lines have proven sensitive
to the lytic activity of H-1PV in vitro. In vivo, parvoviruses
have been shown to exert oncosuppressive activity against
implants of tumor cells, including human neoplastic cells,in recipient animals [8]. Parvovirus H-1PV shows poor on-
colytic activity in colon carcinoma models. Colon carci-
noma cell lines are sensitive to H-1PV killing, but only
at high MOIs and after a long incubation period (8 days).
H-1PV infection of colon carcinoma cells leads to produc-
tion of cytotoxic NS-1 protein, but the ability of the virus
to replicate is impaired in colon cancer cells [9,10].
In addition to direct virus-induced oncolysis, an immune
component also appears to contribute to parvovirus-
mediated oncosuppression. We have previously shown
that parvovirus H-1PV, in addition to killing pancreatic
cancer cells, can also induce these cells to activate NK cells
and boost the innate immune system through enhanced
production of IFN-γ and TNF-α [11]. Therefore, oncolytic
viruses should be tested further for the ability to augment
antitumor immune responses in colon carcinoma. No colon
carcinoma model has yet been tested for immune modula-
tion induced by parvovirus-H-1PV.
In the present study we show that IL-2-activated NK
cells can effectively kill colon carcinoma cells. We also
demonstrate that parvovirus H-1PV infection of colon
carcinoma cells can enhance NK-cell-mediated killing of
these cells, and that the cytotoxicity of NK cells towards
mock- and H-1PV-infected colon carcinoma cells is medi-
ated mostly by a combination of natural cytotoxicty recep-
tors, namely NKp30, 44, and 46. We evidence moderate
modulation of NCR ligands in colon carcinoma cells upon
infection with H-1PV. Lastly, we show that lysates of H-
1PV-infected colon carcinoma cells cause an increase in
MHC class II expression on dendritic cells.
In conclusion, our data show that NK cells can kill colon
cancer cells and suggest that H-1PV-based immunother-
apy might increase NK-cell-mediated immune responses,




Human NK cells were isolated by negative depletion
from peripheral blood lymphocytes by means of an NK-
cell isolation kit (Dynal, Karlsruhe, Germany). The NK
population consisted of 90% - 99% cells displaying the
CD3− CD56+ phenotype. NK cells were expanded in the
presence of IL-2 (100 IU/ml) (NCI-FCRC, preclinical re-
pository) for 5–8 days in RPMI, 10% FCS, penicillin/
streptomycin (Invitrogen, Karlsruhe, Germany). They were
also obtained by co-culturing peripheral blood mononu-
clear cells (PBMCs) and irradiated RPMI 8866 cells, as
described elsewhere [11]. Alloreactive CD8+ T-cells were
isolated from the blood of healthy donors with the Dy-
nabeads Untouched human CD8+T-cell kit (Invitrogen,
Norway) according to the manufacturer’s instructions. They
were stimulated with IL-2 (100 IU/ml) for a week. Human
DCs were prepared from freshly drawn blood from healthy
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method or with the Dynabeads Untouched human mono-
cyte kit (Invitrogen, Norway) according to the manufac-
turer’s instructions. For the adherence method, PBMCs
were washed twice with phosphate-buffered saline (PBS)
and resuspended in X-Vivo 15 medium (BioWhittaker)
supplemented with 2 mM L-glutamine, 50 U/ml penicillin,
and 50 μg/ml streptomycin. The PBMCs were plated at
the density of 6 × 106 cells/ml. After incubation at 37°C
for 2 h or overnight, non-adherent cells were removed
by washing with PBS. Adherent monocytes were cul-
tured for 6 days in X-vivo 15 medium supplemented
with 1000 IU/ml IL-4 (Promokine, Promocell, Heidelberg,
Germany) and 500 IU/ml granulocyte macrophage–colony-
stimulating factor (Leukine, Uni-apotheke, Heidelberg,
Germany). Colo32, SW480, HT29, and Lovo cells were
maintained in monolayer cultures under standard condi-
tions (37°C, 5% CO2) in DMEM/RPMI medium supple-
mented with 10% FCS, glutamine, and antibiotics.
H-1PV infection and lysate preparation
H-1PV was produced by infection of NB-324 K cells. Re-
combinant H-1PV expressing the marker EGFP (Chi-hH1/
EGFP) was obtained by transfection of 293 T cells, as de-
scribed previously [12]. Virus infections were performed at
37°C for 1 h with a small inoculum of purified virus (wild-
type H-1PV or Chi-hH1/EGFP) with occasional rocking of
the plate. Mock infection was performed by incubating the
cells with FCS-free DMEM medium only. Virus stocks
were purified by iodixanol gradient centrifugation and ti-
trated either by plaque assay or by infected cell hybrid-
ization assay on NB-324 K indicator cells. Virus titers are
expressed in plaque forming units (PFU) or replication
units (RU) per milliliter of virus suspension, as described
elsewhere [12-14]. For lysate preparation, mock- and H-
1PV-infected cells were harvested, centrifuged, and washed
with PBS. The pellets were resuspended in PBS and freeze-
thawed four times by alternative immersion in liquid N2
and a water bath maintained at 37°C, with occasional vor-
texing. The lysates were then centrifuged at 4°C and
13000 rpm for 30 minutes. The protein content of the ly-
sates was estimated by measuring the absorbance at 280
nM with a Nanodrop instrument.
FACS analysis and antibodies
The following antibodies were used: anti-CD56 (iso-
type IgG2a) and anti-CD3 (isotype IgG1, Immunotools,
Friesoythe, Germany) coupled, respectively, with FITC or
PE (BD Biosciences, Heidelberg, Germany). Antibodies
against NCRs (NKp46-clone 9E2, NKp44-clone P44-8,
NKp30-clone P30-15), CD16 (clone 3G8), (Biolegend, CA),
DNAM-1, and NKG2D (R&D systems, Germany) were
used in neutralization assays at 10 μg/ml concentration.
Mouse IgG1 (MOPC-21-Biolegend, CA) was used as anisotype control. Antibodies against NKG2D ligands (MI
CA/B and ULBP1/2) were a kind gift from A. Cerwenka,
DKFZ, Heidelberg). Antibodies against DNAM1 ligands
(PE-coupled CD155 and CD112) were purchased from Bio-
legend, CA. Antibodies against CD40 (clone HI40a), CD80
(clone MEM-233), CD86 (clone BU63), and MHC class II
(clone MEM-12) were purchased from Immunotools
(Friesoythe, Germany). For FACS staining, cells were
suspended in 50 μl FACS buffer (PBS, 2% FCS) and incu-
bated with antibodies for 20 min on ice. All washing steps
were performed with cold FACS buffer. The cells were then
immediately analyzed on a FACS Scan (BD Biosciences,
Heidelberg, Germany).
To investigate the expression of NCR ligands, we
used recombinant human NKp30-IgGfc, NKp44-IgGfc, and
NKp46-IgGfc fusion proteins (R & D Systems, Minneapolis,
MN). Staining of NCR ligands was performed by adding
5 μl reconstituted IgG fc fusion protein to 3 × 105 cells in a
100-μl volume and incubating for 2 h on ice without
blocking. After washing with cold PBS, the cells were
incubated with FITC-conjugated goat anti-human IgG
fcγ secondary antibody (Jackson ImmunoResearch) for
30 minutes in the dark. The cells were then washed and
used for FACS analysis.Cytotoxicity assay
Target cells grown to mid-log phase (5 × 105 cells) were
labeled for 1 h at 37°C in 100 μl CTL assay medium
(RPMI with 10% FCS and penicillin/streptomycin) with
100 μCi 51Cr (Perkin Elmer, Germany). Target cells (T)
were washed twice and resuspended in assay medium.
Effector cells (E) were seeded onto a V-bottom 96-well
plate with 5000 target cells/well at different E:T ratios
and, after a 2-min low-speed centrifugation, incubated at
37°C for 4 h in the presence of 100 IU/ml IL-2. Max-
imum release was determined by treating target cells
with 1% Triton X-100 (Sigma, Germany). For spontaneous
release, targets were incubated without effectors in assay
medium alone. In inhibition assays, effector cells were incu-
bated with mouse anti-human NKG2D, CD16, NCRs, or
DNAM-1 antibodies or with the mouse isotype MOPC-21
at 10 μg/ml final concentration for 1 h before mixing with
target cells. All samples were tested in triplicate. Superna-
tants were harvested and 51Cr release was measured in a
gamma counter. The percentage of specific release was cal-
culated as follows: (experimental release-spontaneous re-
lease)/(maximum release-spontaneous release) × 100.Ethics statement
Primary human NK cells were isolated from buffy coats
purchased from the Institute for Clinical Transfusion Medi-
cine and Cell Therapy, Heidelberg. The Ethics Committee
of the University of Heidelberg permitted the use of buffy
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Results
IL-2-activated NK cells effectively target colon
carcinoma cells
In vitro 51Cr release assays were performed to test the
(heretofore unknown) capacity of NK cells to kill colon car-
cinoma cells. NK cells isolated from healthy donors were
stimulated with IL-2 (100 IU/ml) for a week or two and
used as effector cells against 51Cr-labeled target colon car-
cinoma cells in a 4-h incubation assay. Using an E:T ratio
ranging from 5:1 to 20:1, we found NK cells to be potent
killers of colon carcinoma cells under these experimental
conditions. In assays performed with NK cells from the
same donors, the tested cell lines displayed differential sus-
ceptibility to killing by NK cells. SW480 and HT29 cells
proved to be the most susceptible (Figure 1a, b), whereas
Lovo and Colo32 cells showed low to moderate susceptibil-
ity (Figure 1c, d). Alloreactive cytotoxic CD8+ T cells from
different healthy donors were likewise stimulated with IL-2
(100 U/ml) and tested for cytotoxicity towards colon car-
cinoma cells. These cells showed only a low level of colon
carcinoma cell killing (Figure 1e). We conclude that IL-2-
activated NK cells may constitute an effective tool for
targeting colon carcinoma cells.
H-1PV treatment of colon carcinoma cells increases NK-
cell-induced killing
As oncolytic viruses appear as novel therapeutic tools
against cancer and as they can have immunomodulating
activities, we examined whether H-1PV might modulate
the action of NK cells against colon carcinoma cells. Having
previously demonstrated that H-1PV infection of pancreaticFigure 1 Killing of colon carcinoma cells by IL-2 -activated NK cells an
cells (Figure 1e) were cultured with IL-2 (100 U/ml) for one week and used
(1a), SW480, (1b) Colo32 (1c), and Lovo (1d) cell lines. NK-cell-mediated ce
SD bars) of triplicates performed with NK cells from one donor. They are re
from three different donors.carcinoma cells, in addition to causing oncolysis, leads to
upregulation of the cytotoxicity of cocultured NK cells [11],
we examined how this parvovirus might affect colon carcin-
oma cells. Colon carcinoma cell cultures were infected for
24 h at MOI = 5 RU/cell with a recombinant H-1PV trans-
ducing the enhanced green fluorescent protein (Chi-hH1/
EGFP). At the end of the incubation period, the proportion
of EGFP-positive cells was determined by FACS as a mea-
sure of the infection efficiency (Figure 2a-d). In this ana-
lysis, the infection efficiency proved to be higher for the
SW480 and HT29 cell lines (Figure 2a, b) than for the Lovo
and Colo32 cell lines (Figure 2c, d).
We then examined whether H-1PV infection of colon
carcinoma cell lines might increase their susceptibility to
killing by IL-2-stimulated NK cells. The colon carcinoma
cell lines were infected with H-1PV (MOI=5 RU/cell) or
mock-treated for 24 h, labeled with 51Cr, and co-incubated
with IL-2-stimulated NK cells at different E:T ratios for 4 h.
Using NK cells from several different donors, we found H-
1PV-infected SW480 cells to be killed by NK cells at a sig-
nificantly higher rate than mock-infected cells (Figure 2e).
Similar results were obtained with HT29 and Lovo cells
(Figure 2f, g). The increase in Colo32-cell death was min-
imal (Figure 2h). No virus-mediated lysis of H-1PV-infected
target cells was seen on day 1 post-infection or after 4 h of
incubation in the killing assays. Altogether, these data sug-
gest that upon H-1PV treatment, colon carcinoma cells
probably undergo phenotypic changes rendering them
more susceptible to killing by NK cells.
Natural cytotoxicity receptors mediate killing of colon
carcinoma cells by NK cells
Having shown that NK cells are potent killers of colon
carcinoma cells, we investigated the mechanism of thisd CD8+T cells. Freshly isolated NK cells (Figure 1a-d) and CD8+ T
as effector (E) cells in 4-h 51Cr release assays performed on the HT29
ll lysis was measured at the indicated E:T ratio. Data are means (with
presentative of independent experiments performed with material
Figure 2 Efficiency of H-1PV infection and NK-cell-mediated killing of mock- and H-1PV-infected colon carcinoma cells. Colon carcinoma
cells were buffer-treated or infected at MOI=5 RU/cell with recombinant H-1PV expressing the marker EGFP (Chi-hH1/EGFP). The proportion of
cells expressing EGFP was determined by flow cytometry. Graphs a-d: gray lines: autofluorescence profiles of mock-treated cells; black columns:
specific staining profiles of Chi-hH1/EGFP-infected. Graphs e-h: Colon carcinoma cells were infected with H-1PV (MOI=5RU/cell) or mock-treated,
incubated for 24 h, and labeled with 51Cr for 1 h. Labeled cells were then incubated with IL-2-activated NK effector cells (E) for 4 h at the
indicated E:T ratio, and cell lysis was measured (Figure 3e-h). The data shown are means with SD bars of the results corresponding to NK cells
from 4 different donors, each measurement being performed in triplicate.
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antibodies targeting various receptors before estimating the
killing effect in 4-h 51Cr release assays. Inhibition of killing
was measured as the percent decrease in cell lysis resulting
from blocking of the tested receptor. All the results were
compared to a control using unrelated MOPC-21 IgG1
isotype. The results highlighted natural cytotoxicity recep-
tors (NCRs) as the major receptors involved in killing of
colon carcinoma cells (Figure 3a-e). Blocking of the NKp30
receptor alone was found to inhibit killing of mock-infected
HT29 cells quite strongly and that of H-1PV-infected cells
to a lesser extent. Combined blocking of the NKp30,
NKp44 and NKp46 receptors proved most effective at
inhibiting killing of both mock- and H-1PV-infected HT29
cells. Similar results were obtained with mock- and H-1PV-
infected Colo32, and SW480 cells (Figure 3b, c). These
observations prove that the NCRs- NKp30, NKp44, and
NKp46 acting together play a major role in mediating the
cytotoxicity of NK cells towards mock- and H-1PV-infected
colon carcinoma cells. Blocking of the NKG2D or NKp44
receptor alone also decreased killing to some extent
(Figure 3a, d). Since it has been shown that CD16 medi-
ates direct NK cell cytotoxicity, in addition to antibody-
dependent cell-mediated cytotoxicity [15], we tested test
whether CD16 receptor blocking could also modulate
Colo 32 cell lysis by NK cells in our experimental
settings under the same assay conditions as for other
blocking antibodies. We observe that CD16 inhibition
also decreased killing of mock and H-1PV infected Colo32
cells but less as compared to combined NCR blocking
(Figure 3b, e).H-1PV infection modulates surface ligand expression on
colon carcinoma cells
To investigate the mechanism by which H-1PV infection
enhances NK-cell-induced killing of colon carcinoma
cells, we analyzed the expression of different ligands and
of MHC class I molecules on mock- and H-1PV-infected
cells. Upon H-1PV infection, MHC class I expression
was found to be down regulated on Lovo cells but un-
changed on the other colon carcinoma cells tested. Nei-
ther the tested NKG2D ligands (ULBP1 and MICA, data
not shown; ULBP2 and MICB, Figure 4a), nor the tested
DNAM1 ligands (CD155 and CD112, data not shown)
showed any upregulation. Our finding that NCRs are
involved in NK-cell-induced killing of colon carcinoma
cells prompted us to test mock- and H-1PV-infected colon
carcinoma cells for expression of NCR ligands, using
NKp30-IgGFc, NKp44-IgGFc, and NKp46-IgGFc fusion
proteins for ligand binding and a secondary antibody to
detect the Fc. Colon carcinoma cells showed moderate ex-
pression of NKp44 ligands and low expression of NKp30
and NKp46 ligands. To determine the effect of H-1PV in-
fection on NCR ligand expression, we infected the colon
carcinoma cells with H-1PV at MOI = 5 and analyzed the
cells on day 1 post infection. Upon H-1PV infection,
HT29, Lovo, and SW480 but not Colo32 cells, displayed
several fold increase in NKp30 ligand expression. Lovo
cells showed an increase in NKp44 ligand expression
after H-1PV infection. HT29 cells exhibited a two-fold
increase in NKp46 ligand expression (Figure 4a).
After this phenotypic assessment of mock- and H-1PV-
infected colon cancer cells, we investigated whether lysates
Figure 3 Role of NK-cell receptors in killing mock- and H-1PV-infected colon carcinoma cells. HT29 and Colo 32 cells (d-e) were
infected with H-1PV (MOI = 5 RU/cell) or mock-treated (a-b) for 24 h and used as targets (T) for IL-2-activated NK effector (E) cells
(E:T=10:1) in 4-h chromium release assays. Prior to their co-incubation with target cells, the effector cells (E) were incubated for 1h with
10 μg/ml blocking antibodies specific to the indicated receptor or with the unrelated MOPC-21 IgG1 isotype. Figure 3c shows results from
uninfected SW480 cells. Data are expressed as percentages of target cell killing and represent means (with SD bars) of triplicate values
from one representative donor. The statistical significance of differences in target-cell lysis was calculated with Student’s t test
(*p, <0.05; **, p<0.01; ***, p<0.001).
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the phenotype of human dendritic cells. Monocyte-derived
dendritic cells were pulsed for 2 days with 50 μg lysate of
mock- or H-1PV-infected Colo32 cells (MOI = 5 pfu/ml).
The lysates were prepared by repeated freezing/thawing
of mock- and H-1PV- infected cells. The dendritic cells
were then analyzed by flow cytometry for surface ex-
pression of CD40, CD80, CD86, and MHC class II. We
failed to detect any change in CD40, CD80, or CD86
expression on dendritic cells treated with either lysate
(data not shown), but MHC class II expression was in-
creased, as compared to untreated cells, when the cells
were treated with lysate of mock-infected Colo32 cells,
and a greater increase was observed upon treatment
with lysate of H-1PV-infected cells (Figure 4b). Altoge-
ther, our results demonstrate that a lysate of H-1PV-
infected cells can upregulate MHC Class II expression
on dendritic cells.Discussion
There is growing interest in exploring the potential of
NK cells in cancer. It appears, however, that during tumor
development, NK cells are in a state of suppression. Cyto-
kines can be used to enhance NK-cell antitumor activity.
Upon activation with cytokines, particularly IL-2, NK cells
can be activated in vitro to exert potent cytotoxicity
against tumors [16]. Here we show that IL-2-activated NK
cells can effectively kill colon carcinoma cells, although
the susceptibility of these cells is variable.
Novel anticancer therapies based on oncolytic viruses are
also emerging. In particular, the oncolytic parvovirus H-
1PV appears as a promising tool for developing such strat-
egies. A major advantage of this virus is that normal human
cells, as opposed to certain cancer cells, are refractory to H-
1PV infection. Yet there is an obstacle to exploiting the
oncolytic properties of H-1PV in the framework of colon
carcinoma: colon carcinoma cells show H-1PV-triggered
Figure 4 Effect of H-1PV infection on the phenotype of colon carcinoma and dendritic cells. (a) Colon carcinoma cells were buffer-treated
(M) or H-1PV-infected (MOI=5 RU per cell), incubated for 24 h, and analyzed by flow cytometry for expression of MHC class I, MICB, and ULBP 2
molecules and NCR (NKp30, NKp44, and NKp46) ligands. Control mouse IgG and specific antibody staining profiles are shown by gray lines and
black columns, respectively. The indicated values represent ΔMFI=MFI (positive)-MFI (isotype/negative control) for one representative experiment
out of three. (b) Colo32 cells were mock-treated (M) or H-1PV-infected (MOI= 5RU/cell) and lysates prepared on day 1 p.i. Dendritic cells were
then pulsed with lysate for 2days and thereafter, analyzed for expression of MHC class II molecules, and compared with untreated dendritic cells.
Figure 4(b) shows the means of data obtained from 3 donors. Control mouse IgG and specific antibody staining profiles are shown by grey lines
and black columns, respectively. The indicated values represent ΔMFI = MFI (positive)-MFI (isotype/negative control).
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and the virus shows impaired replication in these cells
[9,10]. This is why we have focused on another property of
H-1PV: its ability to enhance killing of cancer cells by NK
cells. This is the first study to examine this property in
colon carcinoma cell models. We clearly demonstrate that
H-1PV infection renders colon carcinoma cells more vul-
nerable to killing by NK cells.
To understand the molecular mechanism of NK cell
cytotoxicity, it is necessary to understand the interaction
between NK cell receptors and tumor ligands [17]. We
show here that the natural cytotoxicty receptors NKp30,
NKp44, and NKp46, unique to NK cells, are involved in
killing the colon carcinoma cell lines tested. As shown
in our experiments where these receptors were blocked,
the combined interaction of these NCRs is primarily re-
sponsible for NK-cell-triggered lysis of both mock- and
H-1PV-infected colon carcinoma cells. This suggests that
the cellular ligands of NCRs, though still elusive, are ex-
pressed on colon carcinoma cells. Our FACS analysis of
NCR ligand expression shows that NCR ligands are present
at low to moderate levels on colon carcinoma cells, butthat H-1PV infection causes several fold increase in NCR
ligand expression. This could account for the increased
killing by NK cells observed upon H-1PV infection. Even
though the upregulation of individual NCR ligands is lim-
ited, it could lead to cumulative activation of the NK-cell
killer effect. Lovo cells, furthermore, showed downregu-
lation of MHC I expression upon H-1PV infection. This, in
addition to NCR ligand upregulation, could lead to in-
creased susceptibility of these cells to killing by NK cells.
Colo32 cells, in contrast, show no increase in NCR ligand
expression upon H-1PV infection. This may explain why
H-1PV-infected Colo32 cells show only minimally in-
creased killing by NK cells. It is important to mention here
that the low level of NKp30 ligand expression in colon car-
cinoma cells does not correlate with the high dependence
of NK cell lysis on NKp30 receptor as shown in antibody-
blocking assays. We speculate that the lack of correlation
could be due to modification of NKp30 ligand(s) in these
cells, leading to their altered recognition by the fusion pro-
teins. Alternatively, other unknown soluble ligand(s) may
be involved, in agreement with a recent report [18]. This
discrepancy has also been reported in other studies [19-21].
Bhat and Rommelaere BMC Cancer 2013, 13:367 Page 8 of 9
http://www.biomedcentral.com/1471-2407/13/367Neither DNAM1 nor NKG2D blocking results in signifi-
cant inhibition of killing of colon carcinoma cells (Figure 3).
Worth mentioning is the fact that colon carcinoma cells
show high-level expression of the DNAM1 ligands CD155
and CD112 (data not shown) but no upregulation upon
H-1PV infection.
Oncolytic virotherapy can release into the tumor mi-
croenvironment a wide range of tumor-associated anti-
gens that can be taken up by antigen-presenting immune
cells such as dendritic cells, so as to prime T cells and
thereby amplify immune responses [22,23]. Parvovirus H-
1PV-induced tumor cell killing has been shown to pro-
mote cytotoxic T lymphocyte responses through increased
phagocytosis, maturation, and cross-presentation by den-
dritic cells [24]. Likewise, significant activation of dendritic
cells and microglia has been observed upon incubation
with parvovirus-MVM-infected glioma cells [25]. Here have
found only a limited effect of H-1PV on the phenotype of
dendritic cells, as only MHC class II expression was up-
regulated upon exposure to H-1PV-infected Colo32-cell ly-
sates. We chose Colo 32 cell-line as these cells are relatively
sensitive to H-1PV infection as compared to other colon
carcinoma cells lines [9,10]. No such effect was observed
with H-1PV-infected Lovo- or HT29-cell lysates. Further-
more, the effect was observed only when 50 μg lysate was
used to treat the dendritic cells. This suggests that opti-
mization of the lysate concentration is important in devis-
ing strategies for immunotherapy.
The present data on the effects of H-1PV on colon
carcinoma cells are consistent with and extend our pre-
vious data showing NK cell activation in response to H-
1PV infection of pancreatic cancer cells. It is noteworthy
that under identical experimental conditions used in this
study, H-1PV infection of normal IL-2 stimulated human
PBMCs failed to activate NK cells as measured through
IFN-γ release [11]. This argues for the tumor specificity
of NK cell sensitization. These data are also in line with
data on other oncolytic viruses, such as reoviruses and
Newcastle disease virus, shown to stimulate innate and
adaptive antitumor activity [22,23]. Here we demonstrate
that upon infection of colon carcinoma cells, H-1PV can
cause neighboring NK cells to exert antitumor activity, even
though the virus’s direct oncolytic effect on these cells is
small. Although the mechanism of action of the parvovirus
remains to be investigated, our results may have therapeu-
tic relevance in the colon carcinoma context. Cytokines,
particularly IL-2, are known to be indispensable to the
regulation of NK-cell cytotoxicity. Previously, we have
demonstrated in a nude-mouse pancreatic cancer model
that the recombinant H-1PVs encoding IL-2 or the che-
mokine MCP-3/CCL7 cause recruitment of activated
NK and monocytes to the site of tumor, resulting in
a strong antitumor response [26]. It would be inte-
resting to evaluate the efficacy of cytokine-encodingparticularly IL-2-encoding and chemokine-encoding)
recombinant H-1PVs in a colon cancer model, too.
Recently, variants of IL-2 have been developed that
caused robust expansion and activation of cytotoxic CD8+
T cells and NK cells but limited expansion of Treg cells,
thereby mitigating adverse effects associated with wild type
IL-2 [27]. Arming of recombinant H-1PV with these novel
IL-2 variants or supplementing H-1PV-based virotherapy
with IL-2 ‘superkine’ is worth considering to improve the
efficiency of tumor therapy.
Conclusions
In conclusion, this study shows that infection of colon
carcinoma cells with H-1PV is immunogenic, causing acti-
vation of innate immune cells in contact with infected
cancer cells. This adjuvant effect of the virus can be ex-
pected to compensate, at least the poor oncolytic effect of
H-1PV on colon carcinoma cells, and to contribute to
oncosuppression. This opens hopeful prospects for the
development of parvovirus-based virotherapies of colon
carcinoma.
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